180 Life Sciences Corp. Expands Patent Portfolio
November 22 2021 - 8:30AM
180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences”
or the “Company”), a clinical-stage biotechnology company focused
on the development of novel drugs that fulfill unmet needs in
inflammatory diseases, fibrosis and pain, today announced that
it has extended its patent portfolio with the recent grant of new
patents to Yissum Research Development Company of the Hebrew
University in both the US (19 Oct 2021, patent no US 11,149,014)
and Canada (26 Oct 2021, patent no CA 2,944,837), which patents the
Company has the exclusive rights to use through its license
agreement with the Yissum Research Development Company of the
Hebrew University.
The patents relate to a method for treating chronic pain or
associated conditions/symptoms with novel compositions that include
certain phenyl substituted cyclohexenyl compounds related to
cannabidiol (CBD); these patents have already been issued for
chronic pain across Europe and validated in 14 jurisdictions (Dec
2020), and China (Jan 2020). These compounds were also initially
described in patents issued in Israel and the US in 2018 and 2019,
respectively, with claims allowed for use in the treatment of
obesity or an obesity associated disease or disorder, which the
Company also has exclusive rights through agreements with the
Yissum Research Development Company of the Hebrew University.
180 Life Sciences is developing synthetic cannabidiol analogues
(SCAs), as part of one of its three preclinical programs, that are
expected to be safe, non-psychoactive and formulated to improve
efficacy and bioavailability for the treatment of pain and
inflammation. The grant of these new patents for the treatment of
chronic pain is an important advance for the SCA preclinical
pipeline.
Dr. James Woody, 180 Life Sciences’ CEO stated, “Our priority
indication is residual pain in patients with established rheumatoid
arthritis (RA), who have not responded adequately to standard of
care therapies. RA is estimated to affect 1% of the global
population and anti-TNF biologics have been shown in many studies
to be very effective in treating joint inflammation in 60-70% of
cases. However, a significant number of patients still require an
alternative to what is currently available. Working through
different mechanisms to commonly used anti-inflammatory RA
medications, we believe that SCAs could offer a complementary
therapeutic strategy for addressing the unremitting pain that
disables many patients.”
About 180 Life Sciences Corp.
180 Life Sciences Corp. is a clinical-stage biotechnology
company focused on the development of novel drugs that fulfill
unmet needs in inflammatory diseases, fibrosis and pain by
leveraging the combined expertise of luminaries in therapeutics
from Oxford University, the Hebrew University and Stanford
University. 180 Life Sciences is leading the research into solving
one of the world’s biggest drivers of disease – inflammation. The
Company is driving groundbreaking studies into clinical programs,
which are seeking to develop novel drugs addressing separate areas
of inflammation for which there are no effective therapies. The
Company’s primary platform is a novel program to treat fibrosis
using anti-TNF (tumor necrosis factor).
Forward-Looking Statements
This press release includes "forward-looking statements",
including information about management’s view of the Company’s
future expectations, plans and prospects, within the safe harbor
provisions under The Private Securities Litigation Reform Act of
1995 (the “Act”). Words such as “expect,” “estimate,” “project,”
“budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,”
“will,” “could,” “should,” “believes,” “predicts,” “potential,”
“continue” and similar expressions are intended to identify such
forward-looking statements. These forward-looking statements
involve significant risks and uncertainties that could cause the
actual results to differ materially from the expected results and,
consequently, you should not rely on these forward-looking
statements as predictions of future events. These forward-looking
statements and factors that may cause such differences include,
without limitation, statements relating to expectations regarding
future agreements relating to the supply of materials and license
and commercialization of products; the availability and cost of
materials required for trials; the risk that initial drug results
will not be able to be replicated in clinical trials or that such
drugs selected for clinical development will not be successful;
challenges and uncertainties inherent in product research and
development, including the uncertainty of clinical success and of
obtaining regulatory approvals; uncertainty of commercial success;
manufacturing difficulties and delays; competition, including
technological advances, new products and patents attained by
competitors; challenges to patents; product efficacy or safety
concerns resulting in product recalls or regulatory action; changes
in behavior and spending patterns of purchasers of health care
products and services; changes to applicable laws and regulations,
including global health care reforms; expectations with respect to
future performance, growth and anticipated acquisitions; the
continued listing of the Company on The NASDAQ Stock Market;
expectations regarding the capitalization, resources and ownership
structure of the Company; expectations with respect to future
performance, growth and anticipated acquisitions; the ability of
the Company to execute its plans to develop and market new drug
products and the timing and costs of these development programs;
estimates of the size of the markets for its potential drug
products; potential litigation involving the Company or the
validity or enforceability of the intellectual property of the
Company; global economic conditions; geopolitical events and
regulatory changes; the expectations, development plans and
anticipated timelines for the Company's drug candidates, pipeline
and programs, including collaborations with third parties; access
to additional financing, and the potential lack of such financing;
and the Company’s ability to raise funding in the future and the
terms of such funding. These risk factors and others are included
from time to time in documents the Company files with the
Securities and Exchange Commission, including, but not limited to,
its Form 10-Ks, Form 10-Qs and Form 8-Ks. These reports and filings
are available at www.sec.gov. All subsequent written and oral
forward-looking statements concerning the Company, the studies
described herein or other matters and attributable to the Company
or any person acting on its behalf are expressly qualified in their
entirety by the cautionary statements above. Readers are cautioned
not to place undue reliance upon any forward-looking statements,
which speak only as of the date made, including the forward-looking
statements included in this press release, which are made only as
of the date hereof. The Company cannot guarantee future results,
levels of activity, performance or achievements. Accordingly, you
should not place undue reliance on these forward-looking
statements. The Company does not undertake or accept any obligation
or undertaking to release publicly any updates or revisions to any
forward-looking statement to reflect any change in its expectations
or any change in events, conditions or circumstances on which any
such statement is based, except as otherwise provided by law.
Investors:
Jason AssadDirector of IR180 Life Sciences Corp(678)
570-6791Jason@180lifesciences.com
Media Relations:
Russo PartnersDavid
SchullDavid.Schull@russopartnersllc.com (212)
845-4271
180 Life Sciences (NASDAQ:ATNF)
Historical Stock Chart
From Mar 2024 to Apr 2024
180 Life Sciences (NASDAQ:ATNF)
Historical Stock Chart
From Apr 2023 to Apr 2024